GS 438

Drug Profile

GS 438

Alternative Names: PMEG

Latest Information Update: 22 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Academy of Sciences of the Czech Republic; Nonindustrial source
  • Developer Gilead Sciences; Nonindustrial source
  • Class Antineoplastics; Antivirals; Nucleotides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections; Human papillomavirus infections; Polyomavirus infections; Solid tumours

Most Recent Events

  • 13 Jun 2005 Preclinical trials in Solid tumours in USA (unspecified route)
  • 13 Jun 2005 Data presented at the 18th International Conference on Antiviral Research (ICAR-2005) have been added to the Cancer pharmacodynamics section
  • 25 Jul 2001 This compound is still in active development as a potential anticancer agent
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top